Bifikafusp Alfa

8 trials 4 recruiting

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

4 Recruiting

3 Completed trials

1 Sponsors

7 Countries

Phase III

Phase II

Phase III: 2 Phase II: 6

Indications tested

Basal cell carcinoma 2 Superficial spreading melanoma stage III 1 Squamous cell carcinoma of skin 1 Malignant melanoma stage III 1

Sponsors using this IMP

Philogen S.p.A. 8

All trials

8 total

A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 … Pending

2024-519326-20-00 Phase II 2 countries Philogen S.p.A.
L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) Recruiting

2025-523229-16-00 Phase II 4 countries Philogen S.p.A.
L19IL2/TNF in patients with basal cell carcinoma Recruiting

2025-523230-77-00 Phase II 4 countries Philogen S.p.A.
L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting

2025-523231-19-00 Phase II 4 countries Philogen S.p.A.
Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Recruiting

2023-507119-36-00 Phase III 4 countries Philogen S.p.A.
L19IL2/L19TNF in skin cancer patients Ended

2024-518531-10-00 Phase II 3 countries Philogen S.p.A.
Neoadjuvant L19IL2/L19TNF- Pivotal study Ended

2024-515749-40-00 Phase III 4 countries Philogen S.p.A.
L19IL2/L19TNF in patients with non-melanoma skin cancer. Ended

2024-518530-92-00 Phase II 2 countries Philogen S.p.A.

Showing 1–8 of 8 trials

← All drugs A–Z